Page 8 - Cv Sciences News Today

CV Sciences, Inc. (OTCQB:CVSI) Q2 2022 Earnings Conference Call August 15, 2022, 10:00 ET Company Participants Joseph Dowling - CEO, Secretary & Director Joerg Grasser - CFO Conference...

/PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp cannabidiol...

/PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp cannabidiol...

If you are confused about which CBD product to buy, learn more from this Plus CBD oil reviews 2023. Pick the right CBD product today.

Farmtiva INC helmed by hemp industry and CBD pioneer Chris Boucher, to lead the resurgence of the stalled Hemp Cannabidiol (CBD) Market, which is set to surpass USD 56.2 billion by 2028, according to a new research report by Global Market Insights Inc., with the launch of JuiceTiva, a revolutionary water soluble, bulk superfood and beverage — “from farm, to Ready-to-Mix”—  raw hemp juice powder, with the highest per gram serving of pure, highly bioavailable CBDa on the market, at the IF...

Equities Research Analysts’ updated eps estimates for Tuesday, May 24th: Central Garden & Pet (NASDAQ:CENTA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $45.00 price target on the stock. According to Zacks, “Central Garden & Pet Company is a leading innovator, marketer […]

CV Sciences (OTCMKTS:CVSI – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals and consumer products. Specialty pharma business segment […]

CV Sciences (OTCMKTS:CVSI – Get Rating) released its quarterly earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02), MarketWatch Earnings reports. CV Sciences had a negative net margin of 77.58% and a negative return on equity of 169.87%. Shares of CVSI traded down $0.00 […]

CV Sciences, Inc. (OTCQB:CVSI) Q1 2022 Results Conference Call May 16, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Scott...

NEW YORK, April 11, 2022 /PRNewswire/ --UNITED STATES DISTRICT COURTDISTRICT OF NEVADAIn re: CV SCIENCES, INC. SECURITIES LITIGATIONCase No. 2:18-...